MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs ...

Metsera (NASDAQ:MTSR ... If it can prove to achieve comparable weight loss to other drugs but offer a far more convenient once-monthly dosing option with its MET-097i drug, plus tolerable safety ...

Guggenheim has initiated Metsera at buy saying that the ... excellent 12-week weight loss seen in a phase 2a trial, and an improved tolerability profile. "If 097i demonstrates acceptable ...

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) is expanding its presence in the weight loss and metabolic disease sector through a strategic collaboration with Metsera, Inc., announced in October 2024.

In preliminary Phase 1b/2a results released in January, the highest dose of the once-weekly injection led to 22% weight loss measured at 36 weeks. Last month, Metsera raised $275 million from its ...

About Metsera Metsera is a clinical-stage biopharmaceutical ... targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based ...

January 31, 2025 Metsera hits $2.7 bln valuation as shares surge 42% in Nasdaq debut Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ...

Oral peptide platform development on track with weight loss and tolerability data for ... dosing and improved tolerability. In February, Metsera completed an IPO, raising approximately $316.2 ...

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq ... dose four-fold higher than the weekly dose continued to lose weight, with an arithmetic mean placebo-subtracted change ...

Metsera is a clinical-stage biopharmaceutical ... targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York ...